WO2006009746A3 - Plasmide possedant trois unites de transcription completes et compositions immunogenes permettant d'induire une reponse immune au vih - Google Patents
Plasmide possedant trois unites de transcription completes et compositions immunogenes permettant d'induire une reponse immune au vih Download PDFInfo
- Publication number
- WO2006009746A3 WO2006009746A3 PCT/US2005/021168 US2005021168W WO2006009746A3 WO 2006009746 A3 WO2006009746 A3 WO 2006009746A3 US 2005021168 W US2005021168 W US 2005021168W WO 2006009746 A3 WO2006009746 A3 WO 2006009746A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasmid
- hiv
- inducing
- immune response
- immunogenic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/60—Vectors comprising a special translation-regulating system from viruses
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05785508A EP1763580A2 (fr) | 2004-06-17 | 2005-06-15 | Plasmide possedant trois unites de transcription completes et compositions immunogenes permettant d'induire une reponse immune au vih |
JP2007516690A JP2008503211A (ja) | 2004-06-17 | 2005-06-15 | 3つの完全な転写単位を有するプラスミドおよびhivに対する免疫応答を誘発するための免疫原組成物 |
US11/629,610 US20070190031A1 (en) | 2004-06-17 | 2005-06-15 | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv |
MXPA06014794A MXPA06014794A (es) | 2004-06-17 | 2005-06-15 | Plasmido que tiene tres unidades de transcripcion completas y composiciones inmunogenicas para inducir una respuesta inmune contra el vih. |
BRPI0512180-9A BRPI0512180A (pt) | 2004-06-17 | 2005-06-15 | plasmìdio de dna; composição imunogênica para induzir uma resposta imune a antìgenos selecionados em um hospedeiro vertebrado; método de imunização de um hospedeiro invertebrado contra antìgenos selecionado; composição imunogênica para induzir uma resposta imune ao vìrus da imunodeficiência humana (hiv) em um hospedeiro vertebrado; método para imunizar um hospedeiro vertebrado contra antìgenos selecionados; composição imunogênica; e uso de uma composição imunogênica |
CA2570114A CA2570114C (fr) | 2004-06-17 | 2005-06-15 | Plasmide possedant trois unites de transcription completes et compositions immunogenes permettant d'induire une reponse immune au vih |
CN200580027023.0A CN101001953B (zh) | 2004-06-17 | 2005-06-15 | 具有三个完整转录单元的质粒和用于诱导hiv免疫反应的免疫原性组合物 |
IL180109A IL180109A0 (en) | 2004-06-17 | 2006-12-14 | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv |
US13/008,694 US8623382B2 (en) | 2004-06-17 | 2011-01-18 | Immunogenic compositions for inducing an immune response to HIV |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58043804P | 2004-06-17 | 2004-06-17 | |
US60/580,438 | 2004-06-17 | ||
US62498304P | 2004-11-03 | 2004-11-03 | |
US60/624,983 | 2004-11-03 | ||
US66227505P | 2005-03-16 | 2005-03-16 | |
US60/662,275 | 2005-03-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/629,610 A-371-Of-International US20070190031A1 (en) | 2004-06-17 | 2005-06-15 | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv |
US13/008,694 Division US8623382B2 (en) | 2004-06-17 | 2011-01-18 | Immunogenic compositions for inducing an immune response to HIV |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006009746A2 WO2006009746A2 (fr) | 2006-01-26 |
WO2006009746A9 WO2006009746A9 (fr) | 2006-03-02 |
WO2006009746A3 true WO2006009746A3 (fr) | 2006-05-11 |
Family
ID=35266872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/021168 WO2006009746A2 (fr) | 2004-06-17 | 2005-06-15 | Plasmide possedant trois unites de transcription completes et compositions immunogenes permettant d'induire une reponse immune au vih |
Country Status (16)
Country | Link |
---|---|
US (2) | US20070190031A1 (fr) |
EP (2) | EP2116605B1 (fr) |
JP (3) | JP2008503211A (fr) |
KR (1) | KR101216278B1 (fr) |
AR (1) | AR049309A1 (fr) |
AU (2) | AU2005265008A1 (fr) |
BR (1) | BRPI0512180A (fr) |
CA (1) | CA2570114C (fr) |
DK (1) | DK2116605T3 (fr) |
ES (1) | ES2386507T3 (fr) |
IL (1) | IL180109A0 (fr) |
MX (1) | MXPA06014794A (fr) |
PL (1) | PL2116605T3 (fr) |
PT (1) | PT2116605E (fr) |
TW (1) | TW200613554A (fr) |
WO (1) | WO2006009746A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ569541A (en) | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
US9173964B2 (en) * | 2007-10-25 | 2015-11-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Diphtheria toxin first open reading frame operably linked to an H19 promoter and a diphtheria toxin second open reading frame operably linked to an IGF-II promoter as nucleic acid construct |
CA2702971C (fr) * | 2007-11-14 | 2023-03-14 | Vgx Pharmaceuticals, Llc | Production d'anticorps provoquee par un vaccin d'adn delivre par electroporation |
US9816086B2 (en) | 2010-07-06 | 2017-11-14 | The Ohio State University | Dose and location controlled drug/gene/particle delivery to individual cells by nanoelectroporation |
SI2794878T1 (sl) | 2011-12-22 | 2020-07-31 | F. Hoffmann-La Roche Ag | Organizacija ekspresijskega vektorja, postopki izdelave nove proizvodne celice in njihova uporaba za rekombinantno proizvodnjo polipeptidov |
KR101457371B1 (ko) * | 2013-01-10 | 2014-11-04 | 강원대학교산학협력단 | 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물 |
FR3004463A1 (fr) * | 2013-04-11 | 2014-10-17 | Genethon | Systeme d'expression pour une therapie genique selective |
US9428767B2 (en) * | 2014-04-09 | 2016-08-30 | Dna2.0, Inc. | Enhanced nucleic acid constructs for eukaryotic gene expression |
US10233454B2 (en) | 2014-04-09 | 2019-03-19 | Dna2.0, Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
EP3359671B1 (fr) | 2015-10-08 | 2021-08-18 | Dna Twopointo Inc. | Vecteurs d'adn, transposons et transposases pour la modification du génome eucaryote |
JP2018038333A (ja) * | 2016-09-08 | 2018-03-15 | ライフテクノロジーズジャパン株式会社 | 細胞の作製方法、発現用ベクター及び細胞 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079518A2 (fr) * | 2000-04-19 | 2001-10-25 | Oxford Biomedica (Uk) Limited | Procede |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6428952B1 (en) * | 1983-09-15 | 2002-08-06 | Institut Pasteur | Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies |
US6600023B1 (en) * | 1983-09-15 | 2003-07-29 | Institut Pasteur | Antibody directed against HIV-1 P25 antigen |
US5843638A (en) * | 1983-12-05 | 1998-12-01 | Institut Pasteur And Centre National De La Recherche Scientifique | Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1). |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5034511A (en) * | 1987-04-13 | 1991-07-23 | Institut Pasteur | Variant of LAV viruses |
US5030714A (en) * | 1986-06-23 | 1991-07-09 | Institut Pasteur | Variant of LAV viruses |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ES2275451T3 (es) * | 1989-06-02 | 2009-02-16 | Institut Pasteur | Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1,vih-2 y siv, y sus aplicaciones especialmente para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones debidas a estos virus. |
US5169784A (en) | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
US5158062A (en) | 1990-12-10 | 1992-10-27 | Ford Motor Company | Adaptive air/fuel ratio control method |
US5118816A (en) | 1990-12-26 | 1992-06-02 | American Cyanamid Company | 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
EP0625052A4 (fr) | 1991-10-21 | 1995-07-19 | Medimmune Inc | Vecteurs d'expression bacteriens contenant de l'adn codant des signaux de secretion de lipoproteines. |
US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
DE4228458A1 (de) * | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
ATE302854T1 (de) | 1993-01-26 | 2005-09-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur verabreichung von genetischem material |
US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US5547862A (en) * | 1993-07-29 | 1996-08-20 | Ambion Inc. | Vectors containing multiple promoters in the same orientation |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US6995008B1 (en) * | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
IL112820A0 (en) * | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
US5585263A (en) | 1994-05-20 | 1996-12-17 | University Of Alabama At Birmingham Research Foundation | Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
CN1651457B (zh) * | 1994-10-20 | 2010-07-28 | 巴斯德研究所 | Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列 |
GB9517263D0 (en) * | 1995-08-23 | 1995-10-25 | Cancer Res Campaign Tech | Expression systems |
WO1997014431A1 (fr) * | 1995-10-20 | 1997-04-24 | Collagen Corporation | Production de procollagene recombinant dans la levure |
US5965440A (en) | 1995-12-07 | 1999-10-12 | The General Hospital Corporation | Controlled gene product delivery from a regulatable retroviral vector |
CA2244110A1 (fr) | 1996-02-12 | 1997-08-14 | Cobra Therapeutics Limited | Nouveaux procedes de vaccination et vaccins associes comprenant un acide nucleique codant un premier epitope, ainsi qu'un peptide contenant un second epitope |
US6225045B1 (en) | 1996-05-13 | 2001-05-01 | Ribotargets, Ltd. | Assays for screening for inhibitors of HIV |
WO1998010088A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 |
US5869326A (en) | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
CA2745736C (fr) | 1996-10-23 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Immunotherapie et vaccins perfectionnes |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
CA2223029A1 (fr) | 1997-02-12 | 1998-08-12 | Akzo Nobel Nv | Vaccins a adn contre des parvovirus canins |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EA002087B1 (ru) | 1997-04-03 | 2001-12-24 | Электрофект Ас | Способ введения фармацевтических препаратов и нуклеиновых кислот в скелетную мышцу |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
WO1999004026A2 (fr) | 1997-07-18 | 1999-01-28 | Chiron Corporation | Vecteurs lentiviraux |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
AU745805B2 (en) | 1997-10-28 | 2002-04-11 | Wyeth | Compositions and methods for delivery of genetic material |
IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
GB9726555D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
BR9908267A (pt) | 1998-02-27 | 2000-10-24 | Univ Pennsylvania | Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo |
AU765177B2 (en) | 1998-03-13 | 2003-09-11 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
JP2002510644A (ja) | 1998-04-03 | 2002-04-09 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物 |
WO1999061596A2 (fr) | 1998-05-22 | 1999-12-02 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Nouveaux elements regulateurs post-transcriptionnels et leurs utilisations |
DE69937571T2 (de) | 1998-09-30 | 2008-09-04 | The Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences | Mutiertes cholera holotoxin als hilfsmittel |
BR0008645A (pt) | 1999-03-03 | 2002-01-22 | Univ Pennsylvania | Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição |
WO2000055335A1 (fr) | 1999-03-16 | 2000-09-21 | Dana-Farber Cancer Institute, Inc. | Vecteurs lentiviraux pseudotypes et utilisations de ces vecteurs |
WO2000066162A1 (fr) | 1999-04-30 | 2000-11-09 | The Trustees Of The University Of Pennsylvania | Cd80 humain mutant, compositions, et technique de preparation et d'utilisation de ces compositions |
ES2341429T3 (es) | 1999-12-23 | 2010-06-21 | Medical Research Council | Mejoras en las respuestas inmunitarias al vih o relacionadas con las mismas. |
DE60042702D1 (de) | 1999-12-23 | 2009-09-17 | Us Gov Health & Human Serv | Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene |
US6589783B2 (en) * | 2000-04-13 | 2003-07-08 | Novagen, Inc. | Multiple host expression vector |
CN1312171C (zh) * | 2000-07-14 | 2007-04-25 | 宾夕法尼亚州立大学托管会 | 可编码hiv辅助蛋白的dna疫苗 |
EP2302059A1 (fr) * | 2000-08-14 | 2011-03-30 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Modifications des protéines Env, Gag et Pol du VIH augmentent l'action immunogénique de vaccins génétiques. |
AU2002346249B2 (en) | 2001-06-07 | 2007-03-15 | The Regents Of The University Of Colorado | Mutant Forms of Cholera Holotoxin as an Adjuvant |
IL159209A0 (en) | 2001-06-07 | 2004-06-01 | Wyeth Corp | Mutant forms of cholera holotoxin as an adjuvant |
ATE340271T1 (de) | 2001-10-22 | 2006-10-15 | Nucleonics Inc | Transfektionskinetik und strukturelle promotoren |
WO2003048366A1 (fr) * | 2001-12-07 | 2003-06-12 | Postech Foundation | Plasmides immunogenes sivmac239 et vaccin a base d'adn contre le sida, les contenant |
CN1490056A (zh) * | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | 针对hiv-1的免疫方法和组合物 |
WO2004093906A1 (fr) * | 2003-03-26 | 2004-11-04 | Wyeth | Compositions et methodes immunogenes |
AU2004279362B2 (en) * | 2003-09-15 | 2011-03-17 | Genvec, Inc. | HIV vaccines based on ENV of multiple clades of HIV |
WO2005068634A1 (fr) * | 2004-01-16 | 2005-07-28 | Pradeep Seth | Vaccins de synthese du sous-type c indien contre le vih-1 a utiliser chez l'homme |
-
2005
- 2005-06-14 TW TW094119582A patent/TW200613554A/zh unknown
- 2005-06-15 DK DK09000063.9T patent/DK2116605T3/da active
- 2005-06-15 ES ES09000063T patent/ES2386507T3/es active Active
- 2005-06-15 EP EP09000063A patent/EP2116605B1/fr active Active
- 2005-06-15 JP JP2007516690A patent/JP2008503211A/ja active Pending
- 2005-06-15 MX MXPA06014794A patent/MXPA06014794A/es active IP Right Grant
- 2005-06-15 KR KR1020077000919A patent/KR101216278B1/ko active IP Right Grant
- 2005-06-15 CA CA2570114A patent/CA2570114C/fr active Active
- 2005-06-15 PT PT09000063T patent/PT2116605E/pt unknown
- 2005-06-15 BR BRPI0512180-9A patent/BRPI0512180A/pt not_active Application Discontinuation
- 2005-06-15 AU AU2005265008A patent/AU2005265008A1/en not_active Abandoned
- 2005-06-15 EP EP05785508A patent/EP1763580A2/fr not_active Withdrawn
- 2005-06-15 WO PCT/US2005/021168 patent/WO2006009746A2/fr active Application Filing
- 2005-06-15 PL PL09000063T patent/PL2116605T3/pl unknown
- 2005-06-15 US US11/629,610 patent/US20070190031A1/en not_active Abandoned
- 2005-06-16 AR ARP050102476A patent/AR049309A1/es unknown
-
2006
- 2006-12-14 IL IL180109A patent/IL180109A0/en unknown
-
2010
- 2010-08-19 JP JP2010184487A patent/JP5264840B2/ja active Active
- 2010-11-08 AU AU2010241303A patent/AU2010241303B2/en active Active
-
2011
- 2011-01-18 US US13/008,694 patent/US8623382B2/en active Active
- 2011-03-09 JP JP2011052047A patent/JP2011115178A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079518A2 (fr) * | 2000-04-19 | 2001-10-25 | Oxford Biomedica (Uk) Limited | Procede |
Non-Patent Citations (3)
Title |
---|
GURUNATHAN S ET AL: "DNA vaccines: a key for inducing long-term cellular immunity", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 12, no. 4, 1 August 2000 (2000-08-01), pages 442 - 447, XP004257702, ISSN: 0952-7915 * |
IWASAKI A ET AL: "ENHANCED CTL RESPONSES MEDIATED BY PLASMID DNA IMMUNOGENS ENCODING COSTIMULATORY MOLECULES AND CYTOKINES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, no. 10, 15 May 1997 (1997-05-15), pages 4591 - 4601, XP002035095, ISSN: 0022-1767 * |
SUTTER G ET AL: "NOVEL VACCINE DELIVERY SYSTEMS: SOLUTIONS TO HIV VACCINE DILEMMAS?", AIDS, LONDON, GB, vol. 15, no. SUPPL 5, 2001, pages S139 - S145, XP009014330, ISSN: 0269-9370 * |
Also Published As
Publication number | Publication date |
---|---|
KR20070029253A (ko) | 2007-03-13 |
AU2005265008A1 (en) | 2006-01-26 |
JP2008503211A (ja) | 2008-02-07 |
IL180109A0 (en) | 2007-05-15 |
JP2010265313A (ja) | 2010-11-25 |
PL2116605T3 (pl) | 2012-10-31 |
JP2011115178A (ja) | 2011-06-16 |
ES2386507T3 (es) | 2012-08-22 |
EP2116605A2 (fr) | 2009-11-11 |
AU2010241303B2 (en) | 2012-09-27 |
BRPI0512180A (pt) | 2008-02-12 |
WO2006009746A2 (fr) | 2006-01-26 |
CA2570114C (fr) | 2013-10-08 |
US8623382B2 (en) | 2014-01-07 |
AU2010241303A1 (en) | 2010-11-25 |
CA2570114A1 (fr) | 2006-01-26 |
TW200613554A (en) | 2006-05-01 |
JP5264840B2 (ja) | 2013-08-14 |
EP1763580A2 (fr) | 2007-03-21 |
WO2006009746A9 (fr) | 2006-03-02 |
EP2116605A3 (fr) | 2010-01-06 |
EP2116605B1 (fr) | 2012-06-06 |
MXPA06014794A (es) | 2007-02-16 |
US20120003265A1 (en) | 2012-01-05 |
AR049309A1 (es) | 2006-07-12 |
DK2116605T3 (da) | 2012-07-09 |
PT2116605E (pt) | 2012-07-24 |
US20070190031A1 (en) | 2007-08-16 |
KR101216278B1 (ko) | 2012-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006009746A3 (fr) | Plasmide possedant trois unites de transcription completes et compositions immunogenes permettant d'induire une reponse immune au vih | |
WO2008115199A3 (fr) | Vaccins viraux chimériques | |
WO2006020071A3 (fr) | Constructions vaccinales et combinaisons de vaccins conçues pour ameliorer l'etendue de la reaction immunitaire a diverses souches et variantes du vih | |
EP0278940A3 (fr) | Antigènes de surface de virus de l'hépatite B et antigènes hybridés les contenant | |
WO2010105251A3 (fr) | Vaccins à vecteurs rétroviraux non intégrants | |
WO2006053871A3 (fr) | Vaccins multivalents comportant des vecteurs viraux recombinants | |
WO2006083301A3 (fr) | Compositions immunogeniques comprenant des polypeptides hmgb1 | |
WO2003038057A3 (fr) | Vaccin genetique contre le virus de l'immunodeficience humaine (vih) | |
WO2004084805A3 (fr) | Polypeptides tat acetyles et procedes d'utilisation de ceux-ci | |
Margolin et al. | Production and immunogenicity of soluble plant-produced HIV-1 subtype C envelope gp140 immunogens | |
DK1092779T3 (da) | Lentiviirusvektorer til fremstilling af immunterapeutiske præparater | |
WO2008026225A3 (fr) | Vaccin contre l'infection par le virus chikungunya | |
WO2010075491A3 (fr) | Expression recombinante de sous-domaines porteurs d'épitopes neutralisants doués d'auto-repliement de l'attachement du virus respiratoire syncytial et protéines hybrides | |
WO2004001051A3 (fr) | Virus de la rougeole recombines exprimant les epitopes d'antigenes d'arn virus, et utilisation dans la preparation de compositions vaccinales | |
WO2016116905A9 (fr) | Antigènes de cmv et leurs utilisations | |
Manfredi et al. | Incorporation of heterologous proteins in engineered exosomes | |
WO2005110492A3 (fr) | Méthode pour utiliser les vecteurs adénovirals amener une réponse immunitaire | |
WO2006078979A3 (fr) | Vecteurs et procedes pour l'immunisation genetique | |
WO2011038473A8 (fr) | Méthode, trousse, plasmide et composition pour induire une réponse immunitaire contre le virus de la dengue, au moyen de vaccins à adn et de virus chimériques | |
WO2004041852A3 (fr) | Vaccin | |
WO2012116142A3 (fr) | Gp96-ig-vis/vih combinée d'origine cellulaire, vaccination par protéine gp120 recombinante pour protection contre le vis/vih | |
WO2007016715A3 (fr) | Preparations induisant une reponse immunitaire | |
Mooij et al. | Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens | |
Sundbäck et al. | Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles | |
WO2018069878A1 (fr) | Production de trimères d'enveloppe de vih solubles dans planta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY CORRECT PAGES 1/12-12/12 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 551898 Country of ref document: NZ Ref document number: 2005265008 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2570114 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11629610 Country of ref document: US Ref document number: 2007190031 Country of ref document: US Ref document number: 06125519 Country of ref document: CO Ref document number: 180109 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/014794 Country of ref document: MX Ref document number: 200610591 Country of ref document: ZA Ref document number: 2007516690 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006502559 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7694/DELNP/2006 Country of ref document: IN |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005785508 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005265008 Country of ref document: AU Date of ref document: 20050615 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005265008 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077000919 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580027023.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1020077000919 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005785508 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11629610 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0512180 Country of ref document: BR |